Gene editing company Precision BioSciences (Nasdaq:DTIL) has announced that preclinical research involving in vivo gene editing targeting hepatitis B virus (HBV) has been published in Molecular Therapy.
In the research, the company used an engineered ARCUS nuclease (ARCUS-POL) targeting the Hepatitis B virus (HBV) genome.
In this preclinical study, ARCUS efficiently targeted and degraded HBV covalently closed circular DNA (cccDNA) by 85%.
Gilead Sciences (Nasdaq:GILD) and Acuitas Therapeutics (Vancouver) collaborated with Precision BioSciences on the research.
“We’re very excited to see this study published in Molecular Therapy and to showcase the compelling reductions in cccDNA and surface antigen obtained with our ARCUS gene-editing platform in two novel animal models of HBV infection,” said Derek Jantz, chief scientific officer of Precision BioSciences, in a news release. …